Drugs / iC9.CAR-CSPG4 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06096038 | Apr 2024 → Sep 2026 overdue | head and neck squamous cell carcinoma, refractory malignant neoplasm | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iC9.CAR-CSPG4 T cells | “autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen (iC9.CAR-CSPG4 T cells)” NCT06096038 ↗ |
| Modality | Cell therapy | “Disease fighting T cells will be isolated and modified to prepare the iC9.CAR-CSPG4 T cells” NCT06096038 ↗ |
| Target | CSPG4 | “against the CSPG4 antigen” NCT06096038 ↗ |